Mirtazapine Bluefish (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2 and 5‑HT3 serotonin receptors, enhancing serotonergic activity. Its antihistamine effect contributes to sedation, supporting mood improvement and sleep.

The appropriate dose of Mirtazapine Bluefish is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to standard prescribing guidelines.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This profile often results in pronounced sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirtazapine Bluefish should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

The medication is taken orally, usually once daily in the evening, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether to swallow tablets whole or with a small amount of liquid.

Serious risks include the potential for agranulocytosis, severe neutropenia, Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts, particularly during the initial weeks of therapy. Prompt medical attention is required if any of these events occur.

Mirtazapine is contraindicated in patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have a known hypersensitivity to the drug. Caution is also advised for individuals with severe hepatic impairment, uncontrolled epilepsy, or a history of severe allergic reactions.